CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Editorial17 Nov 201

JOURNAL:Circulation. Article Link

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF

Martinez FA, Serenelli M, Nicolau JC et al. Keywords: dapagliflozin; HFrEF; efficacy; safety

FULL TEXT PDF